NCT05798234 (CO-OHD) is a clinical trial of high flow oxygen device in COVID-19 Pneumonia, sponsored by Central Hospital, Nancy, France.

Who is sponsoring NCT05798234?

NCT05798234 is sponsored by Central Hospital, Nancy, France.

What drugs are being tested in NCT05798234?

Interventions in NCT05798234: high flow oxygen device.

What condition does NCT05798234 study?

NCT05798234 studies COVID-19 Pneumonia.

Is NCT05798234 still recruiting?

NCT05798234 is currently status unknown. Last updated 4 April 2023.

Last reviewed 2023-04-04 · How we verify

NCT05798234: CO-OHD

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Factors Associated With Failure of HFNO in COVID-19 ICU Patients

Status unknown Last updated 4 April 2023

What this trial tests

trial testing high flow oxygen device in COVID-19 Pneumonia in 500 participants. Status unknown.

Timeline

1 May 2023

Primary endpoint
1 September 2023

1 December 2023

Quick facts

Lead sponsor	Central Hospital, Nancy, France
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	500
Start date	1 May 2023
Primary completion	1 September 2023
Estimated completion	1 December 2023
Sites	1 location across France

Drugs / interventions tested

high flow oxygen device

Conditions studied

COVID-19 Pneumonia — all drugs for COVID-19 Pneumonia →

Sponsor

Central Hospital, Nancy, France

Who can join

18 and older, any sex, with COVID-19 Pneumonia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To determine the factors associated with OHD failure in COVID-19 patients admitted to an Intensive Care Unit

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for COVID-19 Pneumonia

Currently open trials in the same condition.

NCT06601998 — Cardiovascular Disease Progression in Survivors of Community Acquired Pneumonia and Lung Infection by Covid-19. · recruiting
NCT06501599 — AI-based System for Assessing Suspected Viral Pneumonia Related Lung Changes · recruiting
NCT06402318 — Passive Detection- SARS-CoV-2 (COVID-19) A&M Breathalyzer (PROTECT Kiosk) for Operational Medicine · recruiting
NCT05765396 — SARS-CoV-2/COVID-19 Study of Next Generation Non-Invasive Passive Detection Technologies · active not recruiting
NCT06927622 — Corona Virus Disease 2019 Cohort Study · recruiting

Other Central Hospital, Nancy, France trials

Trials by the same sponsor.

NCT06452290 — PET Biomarker Study for Antidepressant Response Prediction in Major Depressive Disorder · NA · not yet recruiting
NCT07518498 — Hypnosis During Mechanical Ventilation Weaning · NA · not yet recruiting
NCT07471334 — Prospective Study of Postictal Psychotic Symptoms Occuring After Video-EEG Monitoring in Focal Epilepsies · NA · not yet recruiting
NCT07414667 — Primary Sjögren's Syndrome: Impact of Quantitative Anti-Ro52 Antibody Analysis on Patient Prognosis and Stratification ( · not yet recruiting
NCT07415759 — Imaging of Electrical Properties by MRI: Investigation of Age-Related Changes · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05798234 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Central Hospital, Nancy, France
Last refreshed: 4 April 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05798234.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing